Aurora Therapeutics: A New Company Is Targeting Phenylketonuria With Gene Editing
Key takeaways
A new company, Aurora Therapeutics, has just launched with 16 million dollars in seed funding from Menlo Ventures.
Co-founded by Jennifer Doudna, Nobel laureate and co-inventor of CRISPR, along with Fyodor Urnov.
Its very first target is phenylketonuria, a condition caused by a wide range of mutations in the PAH gene.
The chosen approach is base editing, which chemically modifies a single letter of DNA without cutting it, making it possible to target several mutations at once.
This is not an available treatment, it’s the start of a research program. But it’s the first time a company of this scale has positioned itself this clearly on PKU with gene editing.
My whole life, I’ve been told that phenylketonuria was forever. A new company, Aurora Therapeutics, might just change that.
Before I go any further, I’d really encourage you to subscribe directly to my blog. That way, you decide what you see, not Facebook, Instagram, or YouTube algorithms deciding for you. And a quick reminder: what I share here comes from my own reading and lived experience. If the topic matters to you, please talk it through with your medical team.
From a vague breakthrough to something much more concrete
Last week, I shared an amazing piece of news. A young man had been cured of a rare disease thanks to a gene-editing technique called “prime editing.” It gave a lot of hope for the future of phenylketonuria, but it was still pretty vague.
Then someone sent me a piece of news that’s even more interesting.
Pioneers in the gene-editing field, including a Nobel Prize laureate, have just launched a new company: Aurora Therapeutics. And here’s the kicker. They’ve secured 16 million dollars in seed funding to start research on genetic correction through base editing. Their very first target? Phenylketonuria.
What’s the difference between prime editing and base editing?
Prime editing nicks one strand of DNA to replace part of the sequence using a template, a small piece of DNA that acts as a model.
Base editing works at a finer level. It doesn’t cut the DNA at all. It chemically modifies a single letter of the genetic code. Think of it as ultra-precise correction fluid for a typo, without tearing the page.
Why this approach matters for us
There are hundreds of possible mutations in the PAH gene, not just one. And that’s exactly where base editing becomes relevant: the technique gives the flexibility needed to address several mutations at once, not just a single version of phenylketonuria.
Alright. I know that’s a lot of science in one go. But for me, what really matters isn’t the technique. It’s that a real company, with real funding, has decided our condition is worth tackling. And after a lifetime of hearing it was forever, that shifts something.
Let’s be honest about the limits
We’re not there tomorrow morning. This is a company that’s just getting off the ground, and the research is just beginning. But the simple fact that we’re talking about it, that resources are being put behind it, that already means a lot.
What about you?
If you live with phenylketonuria like me, does this kind of news give you hope, or do you prefer to wait and see? Drop me a comment, I’d really like to know where we all stand on this, together.
I’m not a doctor, a researcher, or a healthcare professional. What I share here reflects my own reading and lived experience as someone who lives with phenylketonuria. For any question about your own situation or treatment, please talk to your medical team.
Source: Aurora Therapeutics, official press release, January 9, 2026 — Aurora Therapeutics Launches to Realize Potential of Personalized Gene Editing for Millions of Patients with Rare Diseases